Antiphospholipid syndrome is a understudied autoimmune disease that is nevertheless a leading causes of deadly blood clots and late-term pregnancy loss. An international study led by the University of Michigan researchers Ray Zuo, M.D., and Jason Knight, M.D., Ph.D., has discovered a new class of functional autoantibodies in APS patients that contributes to the disease’s development and the systemic inflammation it induces.
Recent studies suggest that APS patients can produce a flurry of overactive immune cells, called neutrophils, that release toxic webs of proteins and DNA called neutrophil extracellular traps, or NETs. These harmful NETs, if not appropriately cleared, can promote inflammation in patients resulting in various clinical complications.
For this study, the team analyzed serum from over 300 APS patients collected by the APS Alliance for Clinical Trials and International Networking international consortium, searching for novel antibodies, called anti-NET antibodies, that might shield the toxic NETs from being destroyed and thereby produce longer lasting noxious effect in the body.
The results reveal elevated levels of the anti-NET in 45% of APS patients worldwide. High anti-NET antibody levels are associated with more circulating toxic NETs in patients’ blood and higher levels of inflammation. The team also found that these anti-NET antibodies promote inflammation via a specific pathway called the complement activation pathway.
“While we have suspected the presence of those antibodies based on what we saw in APS patients here at the University of Michigan, this large international study confirmed that these functional anti-NET antibodies are indeed present across a diverse cohort of international patients,” said Zuo, lead author and a rheumatologist at Michigan Medicine. “They likely feed into the inflammatory storm responsible for many complications of APS.”
Beyond blood clots and adverse pregnancy outcomes, many APS patients suffer from other less-recognized clinical complications, such as low platelet counts, heart valve disease, seizure disorder, kidney damage, and brain lesions. There are few clinically relevant tests that can help physicians predict which APS patients are at risk for these non-clotting complications. The researchers also found that anti-NET antibodies were associated with developing brain “white matter” lesions, which potentially affect the brain’s ability to efficiently conduct signals.
“While further studies are needed,” said Knight, co-corresponding author of the paper and an associate professor of rheumatology at Michigan Medicine. “Anti-NET antibodies have the potential to help physicians identify patients at risk for certain complications such as the abnormal brain changes that may contribute to difficulties with thinking and memory.”
This study stems from APS ACTION, an international research consortium supporting large-scale, multicenter clinical and translational research in APS patients. The consortium has enrolled almost 1,200 antiphospholipid antibody-positive patients as of March 2023, with a collection of detailed demographic and clinical information and blood specimens spanning up to 10 years.
“APS is a relatively rare disease,” said Knight. “Without the support of APS ACTION researchers and participants around the world, this study would not have been possible.”
“APS ACTION is a unique international research collaborative effort with 43 centers around the globe, including the University of Michigan, open to qualified investigators who are committed to further our understanding of APS and its management,” said Doruk Erkan, M.D., M.P.H, founder member and executive committee co-chair of the APS ACTION, Professor of Medicine at Hospital for Special Surgery and Weill Cornell Medicine, New York, NY. “We will continue to support innovative research and brilliant minds such as Dr. Zuo and Dr. Knight, who are passionate about finding a cure to APS.”
NETs themselves are a mixture of DNA, numerous proteins, and other inflammatory molecules, any of which could be targets for “anti-NET antibodies.” Utilizing a state-of-the-art hig-throughput platform, the team uncovered several specific targets of the identified anti-NET antibodies. Follow-up studies are underway to dive deeper into these particular molecular targets and their associated pathways.
“The better we understand these anti-NET antibodies and their functions, the more equipped we will be to design better therapeutic for APS patients,” Zuo said. ” As these anti-NET antibodies have been reported in other autoimmune diseases, studying these antibodies will also teach us about the mechanisms of autoimmunity in general.”
Additional Authors: Yu Zuo, MD, Sherwin Navaz, BS, Katarina Kmetova, MS, Lyndsay Kluge, Amala Ambati, MD, Claire K. Hoy, BS, Srilakshmi Yalavarthi, MS, and Jason S. Knight, MD, PhDfrom the Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Alex Tsodikov, PhD from the School of Public Health, University of Michigan, Ann Arbor, MI, USA. Danieli de Andrade, MD, PhDfrom the University of São Paulo, São Paulo, Brazil. Maria G. Tektonidou, MD, PhDfrom the National and Kapodistrian University of Athens, Athens, Greece. Savino Sciascia, MD, PhDfrom the University of Turin, Turin, Italy. Vittorio Pengo, MD from Padova University Hospital, Padova, Italy. Guillermo Ruiz-Irastorza, MDfrom the Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain. H. Michael Belmont, MDfrom the New York University Langone Medical Center, New York, NY, USA. Maria Gerosa, MD, PhDfrom the University of Milan, Milan, Italy. Paul R. Fortin, MDfrom CHU de Québec- Université Laval, Quebec, QC, Canada. Guilherme Ramires de Jesus, MDfrom Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. D. Ware Branch, MDfrom the University of Utah and Intermountain Healthcare, Salt Lake City, UT, USA. Laura Andreoli, MD, PhDfrom the University of Brescia, Brescia, Italy. Esther Rodriguez-Almaraz, MDfrom the Hospital Universitario 12 de Octubre, Madrid, Spain. Michelle Petri, MDfrom Johns Hopkins University School of Medicine, Baltimore, MD, USA. Ricard Cervera, MDfrom the Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain. Rohan Willis, MDfrom the University of Texas Medical Branch, Galveston, TX, USA. David R. Karp, MD, PhDfrom the Division of Rheumatic Disease, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Quan-Zhen Li, MD, PhDfrom the Department of Immunology, Immune Phenotyping Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, USA.Hannah Cohen, MDfrom the Haemostasis Research Unit, Department of Haematology, University College London, London, UK. Maria Laura Bertolaccini, PhDfrom the King’s College London British Heart Foundation Centre of Excellence, London, UK. Doruk Erkan. MDfrom the Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA.
Funding was received by NIH, Rheumatology Research Foundation.
